Safety
Crixivan (indinavir sulfate) Capsules
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- April 2008
| The detailed view includes drug products with safety labeling changes to the BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, or PATIENT PACKAGE INSERT/MEDICATION GUIDE sections. Deletions or editorial revisions made to these sections are not included in this summary. Read about the new physician labeling format. |
| Sections Modified | Summary of Changes to Contraindications and Warnings |
|
CONTRAINDICATIONS
WARNINGS
PRECAUTIONS
PATIENT PACKAGE INSERT
|
CONTRAINDICATIONS Table 7: Drug Interactions With Crixivan: Contraindicated Drugs Drug Class: Sedative/hypnotics Oral midazolam (added as contraindicated drug) (See highlighted text for labeling revisions.) WARNINGS Drug Interactions Caution should be exercised if HIV protease inhibitors, including Crixivan, are used concurrently with other HMG-CoA reductase inhibitors that are also metabolized by the CYP3A4 pathway (e.g., atorvastatin or rosuvastatin). ...If Crixivan with or without ritonavir is co-administered with parenteral midazolam, it should be done in a setting which ensures close clinical monitoring and appropriate medical management in case of respiratory depression and/or prolonged sedation. Dosage reduction for midazolam should be considered, especially if more than a single dose of midazolam is administered. |







